High Dose Intravenous Furosemide for the Management of Acute Cardio-Renal Syndrome

Length of Stay (Days) 6.4679 7.1667 6.6209 5.85 7.39 4.9 5 4.3 (N5 187,565) Inpatient Mortality (%) 0 4 1.55 0.04 3.14 2.8 3.9 3.8 (N5 187,565) Conclusions: Nearly one third of patients in our DMP had preserved EF for whom effective management strategies do not exist. With the exception of BNP and hematocrit, the clinical and prognostic factors were not significantly different between the two groups. The prognostic role of lower hematocrit in HF with preserved EF needs to be further investigated. Management of comorbidities may be important in HF regardless of EF. ACE-I/ARB (%) 60 64 61.89 56.26 67.52 58 71 63 (N5 140,841) Beta-Blockers (%) 74 85 79.37 74.68 84.06 52 62 64 (N5 140,841)